Company Overview of Octapharma AG
Octapharma AG, a plasma fractionation company, develops, produces, and sells human proteins that are derived from human plasma and human cell-lines in Europe and internationally. It offers haematology products, such as Nuwiq, a human coagulation factor VIII recombinant DNA for the treatment and prophylaxis of bleeding in all age groups with haemophilia A; octanate, a human factor VIII/von Willebrand factor (VWF) concentrate, which is used for the prophylaxis and treatment of bleeding in haemophilia A patients; wilate, a human VWF concentrate to treat von Willebrand disease and haemophilia A patients; and octanine F, a human factor IX concentrate for the prophylaxis and treatment of bleeding ...
Founded in 1983
Key Executives for Octapharma AG
Chairman of Management Board and Chief Executive Officer
Chief Financial Officer and Member of Management Board
Member of Management Board and President of Octapharma Plasma Inc USA
Member of Management Board and President of Octapharma USA INC
Senior Vice President of R&D Plasma - Vienna
Compensation as of Fiscal Year 2017.
Octapharma AG Key Developments
Octapharma AG Announces Earnings Results for the Year 2017
Mar 1 18
Octapharma AG announced earnings results for the year 2017. For the year, the company reported gross profit in 2017 is €592 million. Operating income is €349 million. Net cash from operating activities is €353 million. Sales of €1.72 billion.
Octapharma AG Presents at Gartner Application Strategies & Solutions Summit 2017, Dec-04-2017 03:45 PM
Nov 13 17
Octapharma AG Presents at Gartner Application Strategies & Solutions Summit 2017, Dec-04-2017 03:45 PM. Venue: Caesars Palace, Las Vegas, Nevada, United States. Speakers: Michael Donham, Director, Information Technology.
Octapharma Announces Publication of Clinical Data Demonstrating Low Immunogenicity and Excellent Efficacy of Nuwiq® in Previously Untreated Patients
Aug 23 17
Octapharma announce the publication of interim data from the NuProtect study (GENA-05,NCT01712438), the first clinical data on treatment with Nuwiq® in previously untreated patients (PUPs), on August 16, 2017 as an Early The NuProtect study was initiated in March 2013 to investigate the immunogenicity, efficacy and safety of Nuwiq® in PUPs with severe haemophilia A, who are at the greatest risk of developing inhibitors. The ongoing study has enrolled 110 PUPs of any age or ethnicity who will receive Nuwiq® for up to 100 exposure days (EDs), making it one of the largest studies with a single FVIII product. Patients who previously received any FVIII concentrates or blood products containing FVIII are excluded from the study. The recently published article describes interim results for 66 PUPs treated for at least 20 EDs, the time by which most inhibitors arise. The cumulative incidence (95% confidence interval) was 20.8% (10.7 "31.0) for all inhibitors and 12.8% (4.5 "21.2) for high-titre inhibitors. The study reported excellent efficacy of Nuwiq® in the prevention of bleeds, with median annual bleeding rates of 0 for spontaneous bleeds and 2.40 for all bleeds. Nuwiq® was also efficacious for the treatment of bleeds (92.4% of bleeds were controlled with one or two infusions) and as surgical prophylaxis (rated as “excellent” or “good” for 89% of surgical procedures). These interim results confirm the excellent haemostatic efficacy reported with Nuwiq® in previously treated patients.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|